In a phase 2 trial, more than half of patients who received neoadjuvant chemotherapy for high-risk upper tract urothelial carcinoma had a pathologic response that was associated with improved survival.
In a small study of patients who underwent radical surgery for upper tract urothelial carcinoma, investigators found no evidence of tract seeding.
In a study, patients diagnosed with a psychiatric illness following their diagnosis of muscle-invasive bladder cancer had a nearly 2-fold increased risk of dying from their cancer.
A single-dose instillation of mitomycin C immediately following therapeutic ureteroscopy upper tract urothelial carcinoma decreased the risk of urothelial recurrence.
Neoadjuvant chemotherapy prior to radical surgery for high-grade upper tract urothelial carcinoma lowered the risk of disease recurrence in the bladder by 66%, a study found.
Urine cytology after an initial TURBT predicted risk for a second TURBT one month later.
Instillation of an investigational mitomycin gel formulation obviated the need for nephrectomy in nearly half of individuals with low-grade upper tract urothelial carcinoma.
New studies find no increase in biochemical recurrence risk following radical prostatectomy or radiation therapy associated with testosterone replacement therapy.
Users of atenolol had 59% and 55% decreased odds of intermediate- and high-risk prostate cancer being found on biopsy compared with nonusers.
Providers should biopsy patients who are on active surveillance for prostate cancer on a regular schedule, according to investigators.
